Clinical Trial Update: AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Refractory to Splenectomy [Phase 3]

View source ↗

Summary

Phase 3 trial update for AMG 531 in thrombocytopenic patients with idiopathic thrombocytopenic purpura (ITP) refractory to splenectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• AMG 531 (AMG531)

Snippet

Sponsor: Amgen | Conditions: Thrombocytopenia, Idiopathic Thrombocytopenic Purpura | Phase 3 | Status: COMPLETED